AMAG Pharma (AMAG) Misses Q4 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to AMAG Pharma (AMAG) Misses Q4 EPS Views

AMAG Pharmaceuticals (AMAG) Offer Positive Risk/Reward, Jefferies Says After Meeting with Management

February 11, 2015 6:38 AM EST

Jefferies analyst Eun Yang reiterated a Buy rating and $55 price target on AMAG Pharmaceuticals (NASDAQ: AMAG) following a meeting with management.

Yang commented, "Focus on AMAG is timing for new asset acquisition & details on Makena life-cycle management strategies - key events for significant... More